XML 32 R22.htm IDEA: XBRL DOCUMENT v2.4.1.9
Fair Value Measurements (Cont Liab and Debt) (Details) (USD $)
0 Months Ended
Jun. 30, 2014
Mar. 31, 2015
Jun. 23, 2014
Apr. 14, 2014
8.00% Convertible Senior Notes Due 2019        
Additional fair value disclosures        
Aggregate principal amount     $ 47,000,000us-gaap_DebtInstrumentFaceAmount
/ us-gaap_LongtermDebtTypeAxis
= tlog_ConvertibleSeniorNotes8.00PercentDue2019Member
 
Interest rate (as a percent)     8.00%us-gaap_DebtInstrumentInterestRateStatedPercentage
/ us-gaap_LongtermDebtTypeAxis
= tlog_ConvertibleSeniorNotes8.00PercentDue2019Member
 
Debt outstanding   43,750,000us-gaap_DebtInstrumentCarryingAmount
/ us-gaap_LongtermDebtTypeAxis
= tlog_ConvertibleSeniorNotes8.00PercentDue2019Member
   
Period from conversion date considered for interest make-whole payment 3 years      
Shape Pharmaceuticals        
Additional fair value disclosures        
Percentage of share capital acquired       100.00%us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired
/ us-gaap_BusinessAcquisitionAxis
= tlog_ShapePharmaceuticalsIncMember
Low end of range of undiscounted amounts       0us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow
/ us-gaap_BusinessAcquisitionAxis
= tlog_ShapePharmaceuticalsIncMember
High end of range of undiscounted amounts       $ 64,500,000us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
/ us-gaap_BusinessAcquisitionAxis
= tlog_ShapePharmaceuticalsIncMember